scholarly journals The real-world evidence of heart failure co-morbidities

2017 ◽  
Vol 19 (3) ◽  
pp. 434-434 ◽  
Author(s):  
Alan Pan
2016 ◽  
Vol 18 (4) ◽  
pp. 402-410 ◽  
Author(s):  
Aldo P. Maggioni ◽  
Francesco Orso ◽  
Silvia Calabria ◽  
Elisa Rossi ◽  
Elisa Cinconze ◽  
...  

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Leszek ◽  
M Zaleska-Kociecka ◽  
D Was ◽  
K Witczak ◽  
K Bartolik ◽  
...  

Abstract Background Heart failure (HF) is the leading cause of death and hospitalization in developed countries. Most of the information about HF is based on selected cohorts, the real epidemiology of HF is scarce. Purpose To assess trends in the real world incidence, prevalence and mortality of all in-and outpatients with HF who presented in public health system in 2009–2018 in Poland. Methods It is a retrospective analysis of 1,990,162 patients who presented with HF in Poland in years 2009–2018. It is a part of nationwide Polish Ministry of Health registry that collects detailed information for the entire Polish population (38,495,659 in 2013) since 2009. Detailed data within the registry were collected since 2013. HF was recorded if HF diagnosis was coded (ICD-10). Results The incidence of HF in Poland fell down from 2013 to reach 127,036 newly diagnosed cases (330 per 100,000 population) in 2018 that equals to 43.6% drop. This decrease was mainly driven by marked reduction in females (p<0.001; Fig. 1A) and HF of ischaemic etiology (HF-IE vs HF-nonIE, Fig. 1B. p<0.001). The HF incidence per 100,000 population decreased across all age groups with the greatest drop in the youngest (Table 1). The prevalence rose by 11.6% to reach 1,242,129 (3233 per 100,000 population) in 2018 with significantly greater increase in females and HF-IE (both p<0.0001, Fig. 1C and D, respectively). The HF prevalence per 100,000 population increased across all age groups except for the 70–79 years old. (Table 1). Mortality increased by 28.5% to reach 142,379 cases (370 per 100,000 population) in 2018. The rise was more pronounced among females (p=0.015, Fig. 1E) and in HF-IE (p<0.001, Fig. 1F). The HF mortality per 100 000 population increased across all age groups, except for the 50–59 subgroup (Table 1). Conclusions Heart failure incidence plummeted in years 2013–2018 in Poland due to drop in newly diagnosed HF-IE. Despite that fact, the prevalence and mortality increased with rising trends in HF-IE. Figure 1. Incidence, prevalence, mortality trends Funding Acknowledgement Type of funding source: Public grant(s) – EU funding. Main funding source(s): The project is co-financed by the European Union from the European Social Fund under the Operational Programme Knowledge Education Development and it is being carried out by the Analyses and Strategies Department of the Polish Ministry of Health


2018 ◽  
Vol 37 (6) ◽  
pp. 491-496
Author(s):  
Gustavo Rodrigues ◽  
António Tralhão ◽  
Carlos Aguiar ◽  
Pedro Freitas ◽  
António Ventosa ◽  
...  

2018 ◽  
Vol 32 (12) ◽  
pp. 2126-2133 ◽  
Author(s):  
B. Strober ◽  
J. Crowley ◽  
R.G. Langley ◽  
K. Gordon ◽  
A. Menter ◽  
...  

2019 ◽  
Vol 51 (3) ◽  
pp. 327-334 ◽  
Author(s):  
Pablo Olivera ◽  
Silvio Danese ◽  
Lieven Pouillon ◽  
Stefanos Bonovas ◽  
Laurent Peyrin-Biroulet

2018 ◽  
Vol 44 (2-3) ◽  
pp. 161-179 ◽  
Author(s):  
Joan H. Krause ◽  
Richard S. Saver

The 21st Century Cures Act (“Cures Act”) relies on the concept of real-world evidence (“RWE”) to improve the Food and Drug Administration (“FDA”) approval process. This has amplified interest and furthered momentum in applying RWE more broadly, beyond FDA regulation. In this article, we discuss the understandable appeal of RWE's pragmatic application and its many potential benefits. But we also caution that claims about RWE's wide-ranging, ameliorative impact on the health care system are likely overstated.The real world of RWE is messy and uncertain. Successfully incorporating RWE into regular health care system decision-making, beyond the FDA, faces considerable obstacles and limitations. We review the reasons to be wary about RWE as a game-changer. These concerns including data reliability, insufficient incentives for stakeholders to generate and engage with high-quality RWE, and lack of comprehensive regulatory oversight. In addition, the push for RWE may impact the enforcement of the health care fraud and abuse laws, perhaps not in necessarily positive ways. Increased reliance on RWE may have significant implications for off-label fraud enforcement, further conflating the distinction between claims that are false for reimbursement rather than for scientific purposes.


2019 ◽  
Vol 22 ◽  
pp. S766
Author(s):  
L. Ramjee ◽  
G. Tremblay ◽  
A. Forsythe

Sign in / Sign up

Export Citation Format

Share Document